Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative Faricimab for Diabetic Vitreous Hemorrhage
NCT06191094Phase 4Enrolling by invitation
- Sponsor
- University of Colorado Denver
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of faricimab in diabetic retinopathy (DR) and Vitreous hemorrhage (VH) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Rates of post-operative vitreous hemorrhage at 6 months. Started Jul 2024; status: enrolling by invitation.
02
Drugs
faricimab
03
Conditions
diabetic retinopathy (DR)Vitreous hemorrhage (VH)
Beyond the preview
Go deeper on NCT06191094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191094.